Singapore, Oct. 27 -- France-based Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, and the Tokyo Metropolitan Institute of Medical Science (TMIMS), have announced their collaboration for the development of a new mpox vaccine using a live-attenuated vaccine.

Mpox is a viral illness caused by the monkeypox virus. It spreads mainly through close contact with an infected person, causing a painful rash, enlarged lymph nodes and fever.

Currently two mpox vaccines recommended by the WHO are in use:

This collaboration aims to develop a new vaccine based on a non-replicating highly attenuated vaccinia virus in most of mammalian cells. This is of interest due to the extremely low p...